From Our 2010 Archives
Antidepressants: Best for Severe Depression?
New Analysis Finds 2 Antidepressants Offer Little Benefit for Less Severe Depression
Reviewed By Louise Chang, MD
Jan. 5, 2010 -- Some antidepressants may work best for people with very severe depression, according to a new analysis, but may provide little or no benefit over placebo for those with mild, moderate, or severe depression.
"For patients with very severe depression, the medication did have a potent effect compared to placebo," says Jay C. Fournier, a psychology graduate student at the University of Pennsylvania, Philadelphia, and lead author of the analysis, published in the Journal of the American Medical Association.
But, he says, "the effects of the active ingredients of the medication were pretty small or nonexistent for patients with mild or moderate depression or even into the severe range."
However, the analysis only looked at two antidepressants.
Effects of Antidepressants: Study Details
Fournier and his colleagues pooled the results of six previously published studies that compared the effects of antidepressants to placebo for 718 adults with varying levels of depression.
Paxil is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor), which is thought to boost mood by making more of the neurotransmitter serotonin available in the brain. Other popular SSRIS include citalopram (Celexa), fluoxetine (Prozac), and sertraline (Zoloft).
Tofranil is an older medication, known as a tricyclic antidepressant, which works by making more of the neurotransmitters serotonin and norepinephrine available.
In the new analysis, Fournier's team only included studies that met their criteria. Studies, for instance, had to have individual patient data, not just overall results.
And the patients evaluated had a broader range of depression severity than those in most studies. Although many other studies only look at severely depressed patients (with a score of 23 or above on a commonly used scale known as the Hamilton Depression Rating Scale), Fournier's team evaluated studies that included patients with scores in the low teens, considered mild or moderate depression, through the 30s, or very severe.
Effects of Antidepressants: Study Results
"We were looking for differences between placebo and medications," Fournier tells WebMD. "We were interested in whether there was a clinically meaningful difference." One way the researchers defined "clinically meaningful" was to have an improvement of three or more points on the Hamilton scale between placebo takers and medicine users.
"The main finding is that the benefit of medication, over and above the placebo, varied as a function of the severity of the depression," he says. "The effect of the medication for the mild, moderate, and even severe fell below this three-point difference that would be clinically significant."
The analysis suggests that some depressed people do respond to placebo, he says, and that severely depressed people are most likely to benefit from antidepressants.
Even so, he tells WebMD, individual treatment decisions should be made in consultation with a physician.
The study results are no surprise to Peter Galier, MD, an internal medicine specialist and former chief of staff at Santa Monica--UCLA Medical Center & Orthopaedic Hospital, Santa Monica, Calif.
"Much like any other disease process, the more severe the disease or symptoms, the more improvement with treatment," he says.
But the analysis doesn't give a complete picture of the effects of antidepressants, says Gregory Asnis, MD, a professor of psychiatry at Albert Einstein College of Medicine and director of the anxiety and depression clinic at Montefiore Medical Center in New York, who reviewed the analysis for WebMD.
"The data is unfortunately skewed to two medications, only one of which [Paxil] is still commonly used," Asnis says.
And Paxil, he finds, can have more side effects, such as sedation and sexual problems, than some of the other SSRI drugs.
The finding of greater differences between placebo and medication in only the severely depressed was not a surprise to him, either, he says. However, he says, the studies were short-term (6 to 11 weeks) and the benefit of the medication could have kicked in later.
"The study contributes to the extensive research that has helped to characterize the role of antidepressants over the years," says Sarah Alspach, a spokeswoman for GlaxoSmithKline, which makes Paxil. "Since its approval by the FDA in 1992, Paxil has helped millions of people battling mental illness lead more productive, happier lives. Antidepressants are an important option, in addition to counseling and lifestyle changes, for treatment of depression."
A spokesperson for Eli Lilly, which makes the antidepressant Prozac, declined comment on the new analysis.
In an email, Alan Goldhammer, vice president of scientific and regulatory affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA), says, "This is a matter best addressed by companies whose drugs were studied and the individual physicians who are tasked with making treatment decisions based on which therapies are best suited for treating their patients."
SOURCES: Jay C. Fournier, graduate psychology student, University of Pennsylvania,